Relapsing Multiple Sclerosis (RMS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Relapsing Multiple Sclerosis (RMS) – Drugs In Development, 2024 report and make more profitable business decisions.
Multiple sclerosis (MS) is the most common disabling neurological disease of young adults with symptom onset generally occurring between the ages of 20 to 40 years. In MS, the immune system cells that normally protect us from viruses, bacteria, and unhealthy cells mistakenly attack myelin in the central nervous system (brain, optic nerves, and spinal cord). Myelin is a substance that makes up the protective sheath (myelin sheath) that coats nerve fibers (axons). Eventually, the disease can cause permanent damage or deterioration of the nerve fibers.
The Relapsing Multiple Sclerosis (RMS) drugs in development market research report provide comprehensive information on the therapeutics under development for Relapsing Multiple Sclerosis (RMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsing Multiple Sclerosis (RMS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Relapsing Multiple Sclerosis (RMS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 17 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Relapsing Multiple Sclerosis (RMS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Relapsing Multiple Sclerosis (RMS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Relapsing Multiple Sclerosis (RMS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Avotres IncBiocure Technology Inc
Biogen Inc
Clene Inc
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Genentech USA Inc
GlobeStar Therapeutics Corp
Novartis AG
Sanofi
UCB SA
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Relapsing Multiple Sclerosis (RMS) reports